Literature DB >> 20488528

Tuberculosis--time to accelerate progress.

Pamela Das1, Richard Horton.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20488528     DOI： 10.1016/S0140-6736(10)60600-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening.

Authors:  Junichi Taira; Koji Morita; Shotaro Kawashima; Tomohiro Umei; Hiroki Baba; Taira Maruoka; Hideyuki Komatsu; Hiroshi Sakamoto; James C Sacchettini; Shunsuke Aoki
Journal:  J Antibiot (Tokyo)       Date:  2017-09-27       Impact factor: 2.649

2.  Evidence from Chile that arsenic in drinking water may increase mortality from pulmonary tuberculosis.

Authors:  Allan H Smith; Guillermo Marshall; Yan Yuan; Jane Liaw; Catterina Ferreccio; Craig Steinmaus
Journal:  Am J Epidemiol       Date:  2010-12-29       Impact factor: 4.897

Review 3.  Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site-specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration.

Authors:  Jacqueline M Achkar; Stephen D Lawn; Mahomed-Yunus S Moosa; Colleen A Wright; Victoria O Kasprowicz
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

Review 4.  Antibody responses to mycobacterial antigens in children with tuberculosis: challenges and potential diagnostic value.

Authors:  Jacqueline M Achkar; Anke Ziegenbalg
Journal:  Clin Vaccine Immunol       Date:  2012-10-24

5.  Listening to Those at the Frontline: Patient and Healthcare Personnel Perspectives on Tuberculosis Treatment Barriers and Facilitators in High TB Burden Regions of Argentina.

Authors:  Sarah J Iribarren; Fernando Rubinstein; Vilda Discacciati; Patricia F Pearce
Journal:  Tuberc Res Treat       Date:  2014-09-28

Review 6.  Smartphone Applications to Support Tuberculosis Prevention and Treatment: Review and Evaluation.

Authors:  Sarah J Iribarren; Rebecca Schnall; Patricia W Stone; Alex Carballo-Diéguez
Journal:  JMIR Mhealth Uhealth       Date:  2016-05-13       Impact factor: 4.773

7.  Levofloxacin-proliposomes: opportunities for use in lung tuberculosis.

Authors:  Wipaporn Rojanarat; Titpawan Nakpheng; Ekawat Thawithong; Niracha Yanyium; Teerapol Srichana
Journal:  Pharmaceutics       Date:  2012-08-13       Impact factor: 6.321

8.  Examining the social status, risk factors and lifestyle changes of tuberculosis patients in Sri Lanka during the treatment period: a cross-sectional study.

Authors:  Madapathage Gayan Buddhika Senanayake; Sumudu Indika Wickramasinghe; Sudath Samaraweera; Pubudu De Silva; Sisira Edirippulige
Journal:  Multidiscip Respir Med       Date:  2018-04-01

Review 9.  Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.

Authors:  H M Adnan Hameed; Md Mahmudul Islam; Chiranjibi Chhotaray; Changwei Wang; Yang Liu; Yaoju Tan; Xinjie Li; Shouyong Tan; Vincent Delorme; Wing W Yew; Jianxiong Liu; Tianyu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2018-04-10       Impact factor: 5.293
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.